CMS CMS Provides an “Update on Open Payments Reporting” at CBI… Thomas Sullivan Aug 19, 2015 0 Hundreds of people flocked to Washington, DC this week for a three-day conference on Open Payments reporting and…
Events Open Payments Data 2014 Suggest Downward Trend in Clinical Research… Thomas Sullivan Aug 18, 2015 1 Could the Sunshine Act be creating an unintentional downward trend in clinical research? An analysis of the U.S. government’s…
Uncategorized Life Science Compliance Update: August Issue Dives Into The Open Payments… Thomas Sullivan Aug 18, 2015 0 The August issue of Life Science Compliance Update provides an interesting look at the recently released 2014 Open…
HHS-OIG OIG Continues Scrutiny of Physician-Owned Distributors of Spinal Devices… Thomas Sullivan Aug 17, 2015 0 Last week, the Department of Health and Human Services Office of Inspector General (OIG) followed up on its recent…
ACCME ABIM and ACCME Announce Collaboration in Support of Physician Lifelong… Thomas Sullivan Aug 14, 2015 0 On August 12, the American Board of Internal Medicine (ABIM) and the Accreditation Council for Continuing Medical Education…
FDA FDA Sends Warning Letter to Duchesnay Inc. Over Social Media Posts From Kim… Thomas Sullivan Aug 13, 2015 0 The Food and Drug Administration (FDA) has evidently been keeping a close eye on Kim Kardashian’s social media pages.…
State Policy The Unintended Consequences of Public Reporting Thomas Sullivan Aug 12, 2015 0 ProPublica Surgeon Scorecard Ad A major concern surrounding ProPublica’s recently released “Surgeon Scorecard” is that rating…
CMS District Court Rules on Reporting Overpayments and False Claims Act… Thomas Sullivan Aug 11, 2015 0 A number of important healthcare decisions have come out of the Southern District of New York over the last week.…
FDA Amarin Wins Preliminary Injunction Against FDA To Promote Truthful… Thomas Sullivan Aug 10, 2015 0 On Friday, a New York Federal Judge ruled that Amarin Pharma is allowed to promote Vascepa, the company's Omega 3…
Uncategorized Hepatitis C Treatments Are Cost Effective Thomas Sullivan Aug 7, 2015 0 Gilead’s Hepatitis C drugs Sovaldi and Harvoni are often targeted for their upfront price, rather than their long-term benefits…